Skip to main content
OpenTrials
Completed

NCT Number: NCT04184700

Epigenetic Effects in Children With Cow's Milk Allergy Treated With Different Formulas

Lactobacillus GG (LGG) is able to exert long lasting effects in children with atopic disorders. Nutramigen LGG accelerates tolerance acquisition in infants with cow's milk allergy. The mechanisms of these effects are still largely undefined. The effect of LGG could be related at least in part by the immunoregulatory role played by LGG. This probiotic can balance the generation of cytokines possibly involved in IgE- or non-IgE-mediated cow's milk allergy Interleulkin (IL)-4, IL-5, IL-10, IFN-γ , TGF-β, and TNF-Υ), which can contribute to modulation of inflammatory processes. The investigators have demonstrated that children with IgE-mediated CMA produce significantly higher level of IL-4 and IL-13 in response to cow's milk protein, and that tolerance is associated with a marked reduction of IL-13 production and a concomitant increased frequency of IFN-γ releasing cells. Epigenetics studies the heritable (and potentially reversible) changes of the genome inherited from one cell generation to the next which alter gene expression but do not involve changes in primary DNA sequences, highlighting the complexity of the inter-relationship between genetics and nutrition. There are three distinct, but closely interacting, epigenetic mechanisms (histone acetylation, DNA methylation, and non-coding microRNAs) that are responsible for modifying the expression of critical genes associated with physiologic and pathologic processes. The profile of epigenetic modifications associated with Th lineage commitment, coupled with the sensitivity of the early developmental period, has led to speculation that factors that disrupt these pathways may increase the risk of allergic diseases. Specifically, effects on DNA methylation and endogenous histone deacetylase inhibitors acting on specific pathways (Th1 and T regulatory cell differentiation) may favour Th2-associated allergic differentiation. MicroRNAs are another structural components of an epigenetic mechanism of post-transcriptional regulation of messenger RNA translation. It has been recently identified a specific Th2-associated microRNA (miR-21) that is critical for the regulation of Th cell polarization. It has been previously demonstrated an inverse DNA methylation pattern of cytokines involved in Th2 response (IL-4, IL-5) compared with cytokines involved in Th1 response (IL-10, INF- y) in children with CMA acquiring oral tolerance, with the most pronounced effects in those treated with Nutramigen LGG.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–12 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pediatric Office

Naples, 80100, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • children with cow's milk allergy

Exclusion criteria

  • Concomitant chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • autoimmune diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • malignancy,
  • chronic pulmonary diseases,
  • malformations of the gastrointestinal tract,
  • suspected eosinophilic esophagitis or eosinophilic enterocolitis,
  • suspected food-protein-induced enterocolitis syndrome,
  • suspected cow's milk protein-induced anaphylaxis,
  • still on exclusion diet with one of the study formulas or with another dietary regimen because of cow's milk allergy,
  • other food allergies.

Treatment and study plan

EHCF+LGG

Dietary Supplement

Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG

RHF

Dietary Supplement

Rice hydrolysed formula

SF

Dietary Supplement

Soy formula

EHWF

Dietary Supplement

extensively hydrolysed whey formula

AAF

Dietary Supplement

amino acid based formula

Primary outcomes

  1. Epigenetic modifications in cytokines genes

    Time frame: 12 months

    TSDR demethylation (prop.) of FOXP3 in children with cow's milk allergy. The primary outcome was the time-averaged FoxP3 Treg-Specific-Demethylation-Region (TSDR) demethylation (prop.), which took into account three repeated measures (0,6,12 months).

Secondary outcomes

  1. Epigenetic modifications in cytokines genes

    Time frame: 6 and 12 months

    Demethtylation rate and expression (fc, fold change, ΔΔCt method)) of FOXP3 in children with cow's milk allergy

  2. Epigenetic modifications in cytokines genes

    Time frame: 6 and 12 months

    Methylation rate (%) of interleukin IL-4, IL-5, IL-10, IFN-γ, in children with cow's milk allergy

  3. Epigenetic modifications in cytokines genes

    Time frame: 6 and 12 months

    Serum levels (pg/ml) of interleukin IL-4, IL-5, IL-10, IFN-γ in children with cow's milk allergy

  4. microRNAs modifications

    Time frame: 12 months

    Expression of miR-125b miR-146a miR-155 miR-29a/b miR-27a miR-128 miR-21 miR-126 miR-145 miR-106a miR-193a5p miR-128

  5. The rate of patients with immune tolerance acquisition to cow's milk protein

    Time frame: 12 months

    Rate of patients with acquisition of tolerance to cow milk protein (rate of patients with outgrown cow's milk allergy)

  6. Concentration of metagenomic characteristics of the intestinal microbiota

    Time frame: 12 months

    evaluation of composition of gut microbiota

  7. Concentration of metabolomic characteristics of the intestinal microbiota

    Time frame: 12 months

    evaluation of function of gut microbiota

Sponsors and collaborators

Lead sponsor

Federico II University

Other

Registry information

Official study title

Epigenetic Effects Involved in Children With Cow's Milk Allergy: A Possible Effect of Hypoallergenic Formulas

Acronym: EPICMA II

Important dates

Study start
2019
Primary completion
2023
Study completion
2024
First posted
Dec 3, 2019
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.